Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 9/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2118021 | 1.00 | P2RX3 (0.44) | P2RX3PIK3CDPDE10ACYP2C9ACHE | |
| SCHEMBL2118050 | 0.89 | KRAS (0.39) | P2RX3CYP2C9ACHEKRASCYP1A2 | |
| SCHEMBL2118042 | 0.89 | KRAS (0.39) | P2RX3CYP2C9ACHEKRASCYP1A2 | |
| SCHEMBL2115352 | 0.86 | CNR2 (0.40) | P2RX3PIK3CDCYP2C9ACHEKRAS | |
| SCHEMBL2115354 | 0.86 | CNR2 (0.40) | P2RX3PIK3CDCYP2C9ACHEKRAS | |
| SCHEMBL2117482 | 0.84 | KRAS (0.40) | P2RX3CYP2C9KRASCYP1A2CYP2D6 | |
| SCHEMBL2117481 | 0.84 | KRAS (0.40) | P2RX3CYP2C9KRASCYP1A2CYP2D6 | |
| SCHEMBL2114702 | 0.82 | P2RX3 (0.38) | P2RX3PIK3CDCYP2C9KRASCYP1A2 | |
| SCHEMBL2114696 | 0.82 | P2RX3 (0.38) | P2RX3PIK3CDCYP2C9KRASCYP1A2 | |
| SCHEMBL2115716 | 0.78 | PIK3CD (0.35) | P2RX3PIK3CDPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | claimed |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | P2RX3 123/4885PIK3CD 6/4885PDE10A 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.